Quince Therapeutics Amends Reverse Split Details, Confirms 1-for-20 Ratio
QNCX sits 17% above its 52-week low of $0.79 on light trading volume (0.1× avg).
Summary
Quince Therapeutics filed an amended 8-K to correct and finalize the details of its previously announced 1-for-20 reverse stock split, effective June 29, 2026.
Key Events · Corporate Governance and Compliance · QNCX
-
Reverse Stock Split Confirmed
The company confirmed a 1-for-20 reverse stock split, effective June 29, 2026, with split-adjusted trading beginning June 30, 2026.
-
Share Count Adjustment
Pre-split, there were 19,559,257 shares outstanding, which will reduce to approximately 977,963 shares post-split. Fractional shares will be rounded up.
-
Amendment to Prior Filing
This 8-K/A amends an earlier 8-K filed on the same day to correct the description of the reverse stock split.
Analysis · QNCX · Life Sciences
This amended filing provides the definitive and corrected details for the 1-for-20 reverse stock split, which was announced earlier today. The reverse split, effective June 29, 2026, is a critical action for the company, likely aimed at maintaining its Nasdaq listing given its history of financial challenges and previous reverse splits. The correction ensures investors have accurate information regarding this significant corporate event.
At the time of this filing, QNCX was trading at $0.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $0.79 to $45.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.